RARE Overview

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.

Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is61.65 USD with a low forecast of 35.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ultragenyx Pharmaceutical Inc revenue for the last quarter amounts to 136.00M USD, decreased -2.36

Ultragenyx Pharmaceutical Inc. EPS for the last quarter amounts to -1.84 USD, increased 17.20

Ultragenyx Pharmaceutical Inc (RARE) has 1371 emplpoyees as of June 23 2026.

Today RARE has the market capitalization of 2.86B USD.